Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. - Wikidata - wikimedia - TriplyDB

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

http://www.wikidata.org/entity/Q36736210

about

Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network Integrated molecular analysis of clear-cell renal cell carcinoma.Medical treatment of renal cancer: new horizons Alterations of Epigenetic Regulators in Pancreatic Cancer and Their Clinical Implications SETD2: an epigenetic modifier with tumor suppressor functionality The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases Renal cell carcinoma.The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.Radiogenomics of clear cell renal cell carcinoma: associations between CT imaging features and mutations.The SWI/SNF Protein PBRM1 Restrains VHL-Loss-Driven Clear Cell Renal Cell Carcinoma.Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma.Genomic Analysis as the First Step toward Personalized Treatment in Renal Cell Carcinoma Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy Impact of recurrent copy number alterations and cancer gene mutations on the predictive accuracy of prognostic models in clear cell renal cell carcinoma.Mutation and expression analysis in medulloblastoma yields prognostic variants and a putative mechanism of disease for i17q tumors.A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma.Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications.VHL, the story of a tumour suppressor gene.Renal cell carcinoma: molecular biology and targeted therapy Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype Identifying molecular genetic features and oncogenic pathways of clear cell renal cell carcinoma through the anatomical (PADUA) scoring system Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma.Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer.Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas.Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival.Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.Histone modifications: implications in renal cell carcinoma.Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors.Cooperation and antagonism among cancer genes: the renal cancer paradigm PBRM1 and BAP1 as novel targets for renal cell carcinoma Management of metastatic kidney cancer in the era of personalized medicine.

P2860

Q26752925-62326F23-E6FA-49B5-B5AF-DD8EF9AA7E13 Q26785930-2A5725F0-E051-49A7-8461-0EF9CB769833 Q27852242-04B38E2C-0C89-4DA0-8563-13BAAA00BDFF Q27852382-951FB880-1F9C-4906-AC0A-6A5F54FB2EE6 Q28073174-9F01DAFC-C9BE-4290-9F8C-85B90AC0DEDB Q28074465-6C52B6C4-0222-4A41-AFFA-5804A94041E2 Q28075731-671CD128-0F33-4F6A-A2A1-D822CC367D01 Q28083152-4A574D02-660E-42D7-BBCE-6FCFFDB29356 Q28397229-269ADD97-6583-4CE5-A18A-C37F4AABC75E Q30235364-8E4D3BC9-93C8-4678-B903-A6BE61FDAC2C Q30277177-82CB9115-979E-4385-BADE-D8144A300C4F Q33570946-5B26FBC3-BCE7-4F74-A3D4-B908B004F811 Q33683959-715A9507-7649-46C4-AFFA-466BA7B875B8 Q33709786-E1ACDAD6-A074-45FC-B678-76444723141B Q33913967-DB6E9F83-3B2D-44D9-B8AA-445C19F7F814 Q33947929-967A7A5C-D412-4192-B279-A238B27BD78B Q34074997-9E63852A-4CAC-4D24-AA26-CC9EFB967C0B Q34098513-BBE15A44-6421-4EA9-A477-04244B88209B Q34108929-63A252B4-EAD7-4AD4-A6A6-44D5B6B082C8 Q34413144-EAE84950-82DB-4A03-9201-05941D92B092 Q34414411-2F7E83DC-F1A7-4923-B5E0-DDF2152277DD Q34455226-036763A8-CC54-4797-A64B-8370A22B9009 Q34513914-0443C0A2-6BDF-4584-BF79-902FCAAE96E3 Q35129478-1A3FA771-ED45-46FC-A767-767666FD91B4 Q35574106-E2F6F9DA-BE82-40F9-8EAE-18EE2CA84A5D Q35667690-06306E7B-9442-4050-ACCE-D9047C741623 Q35915304-BDA9FD90-1EB1-4299-B867-4227BBD8A25A Q36716606-AAEAB094-28CE-4737-812E-53D9AF2E392A Q36783309-F19B52F5-0D37-4AA0-91C2-7FC7F41788FD Q36832167-8586DB2B-E07A-4E27-A5F3-9054226F7C47 Q37016755-D6039586-874C-4DB4-8CF6-C5DD649DB56F Q37114357-53589882-0C2A-4340-9036-8E3D85C1F9C4 Q37172780-F0E4EA30-9DA3-4AE5-A000-D37A5E443E91 Q37330688-031612EE-C5B7-4FE9-A493-54F2E3FBD4F4 Q37414110-96FA3A8D-6257-4940-9D27-8E3969CF459F Q37550216-E34711B2-C471-4273-BCF3-90F4E6CFC154 Q38116001-41CF1765-E4BA-4CBA-9E38-12FA30F974E7 Q38119888-30A3A764-8A95-4D36-B039-72964F1E7818 Q38122565-DE8B0E2C-5672-43E0-98AD-A063114FC192 Q38180744-CD484105-6E62-48DB-B099-C6BF62488AFC

P2860

Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma.

http://www.wikidata.org/entity/Q36736210

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Clinical and pathologic impact ...... ear cell renal cell carcinoma.

@ast

Clinical and pathologic impact ...... ear cell renal cell carcinoma.

@en

type

label

Clinical and pathologic impact ...... ear cell renal cell carcinoma.

@ast

Clinical and pathologic impact ...... ear cell renal cell carcinoma.

@en

prefLabel

Clinical and pathologic impact ...... ear cell renal cell carcinoma.

@ast

Clinical and pathologic impact ...... ear cell renal cell carcinoma.

@en

P1433

Q36736210-FDF33510-9B47-4C09-BC86-EE0CD41F4245

P1476

Q36736210-8DFA9143-0972-42A0-8C19-33F5C1BAEA1B

P2093

Q36736210-0CFEE337-2509-4912-B7F2-333F5505044D

Q36736210-1BDEF0EB-F0FF-470B-9A13-C36EE07F9C4E

Q36736210-34C2053D-0507-420B-A87E-170C790F9BF0

Q36736210-39463210-2639-4669-A52D-5D91C1D6CA3C

Q36736210-6505258E-4E05-44BB-9765-985E27C93BE4

Q36736210-71F9C712-84EA-403E-874E-CC82AF39443C

Q36736210-7785E7C5-F76A-4D82-85DB-1E9DC61F1F5E

Q36736210-ADCE000A-4B49-4F6C-A39E-A98DE002E440

Q36736210-B513E2CC-B3DD-4E27-AB00-A27ED151BE86

Q36736210-CB386A59-4189-4BC4-B4FD-0B662D1D1E43

P2860

Q36736210-1649736F-F87C-46AA-A56C-6FDC6C84F1E4

Q36736210-214D669A-A2DA-448D-A7A4-B8919966438E

Q36736210-24AF911E-2EFF-4975-8106-14CFB7123806

Q36736210-2A41ED23-DA54-4573-A518-6AF57E3E4907

Q36736210-3D283AC5-8267-4E3D-99BD-895D2846AC1C

Q36736210-4420EA0E-7D01-4202-BE68-8137CB6D8373

Q36736210-5462998A-1C66-4CBE-9EAD-BE263888AC89

Q36736210-56B8B414-7BEF-46B6-9D54-C66A0091827C

Q36736210-593C0789-07B6-46DD-9BF7-BA6F719E6EA1

Q36736210-5FF3AA34-4CC6-4C1C-9B6A-E9F3CB8C3D57

P304

Q36736210-0E4364A8-C197-4BFE-AFC6-83DF8D063EC7

P31

Q36736210-71FE6765-7F71-4C1F-88F0-C921D7548509

P356

Q36736210-6D49BD07-BCA0-4683-8A88-FC2C3242F6BC

P407

Q36736210-1E8F4647-2313-4CB3-8B95-65AB831153FF

P433

Q36736210-364067F8-70E8-4A38-A8EE-BF470BDAA914

P478

Q36736210-178E95B8-01DD-4B3B-878F-E73F85CEAFB4

P50

Q36736210-AA1D8C50-ECD5-4823-9406-3B10C67FAE27

Q36736210-BD50BD94-E699-4C41-A583-734BFF20AA55

Q36736210-C4DDB615-46B4-4A64-B05B-05BBD522AAF5

Q36736210-CB52C19B-4BBF-4FC0-A2DB-CDAE4F182A2C

Q36736210-E9053E24-E5A9-48ED-A8C8-22399577DAF2

P577

Q36736210-EB45A0B8-7A7D-4F98-A34E-1E7806998F2B

P5875

Q36736210-15AF0E95-81AE-40DA-9D3A-AC96E6409C27

P698

Q36736210-21E1F8E8-C83A-455A-8522-A0134F8364F5

P932

Q36736210-86075A91-471B-41C4-A1CB-0C104C2B8ABA

P356

J.EURURO.2012.09.005

P1433

European Urology

P1476

Clinical and pathologic impact ...... ear cell renal cell carcinoma.

@en

P2093

A Ari Hakimi

http://www.w3.org/2001/XMLSchema#string

Adriana Heguy

http://www.w3.org/2001/XMLSchema#string

Emily H Cheng

http://www.w3.org/2001/XMLSchema#string

Han Liu

http://www.w3.org/2001/XMLSchema#string

James J Hsieh

http://www.w3.org/2001/XMLSchema#string

James Wren

http://www.w3.org/2001/XMLSchema#string

Martin H Voss

http://www.w3.org/2001/XMLSchema#string

Mithat Gonen

http://www.w3.org/2001/XMLSchema#string

Paul Russo

http://www.w3.org/2001/XMLSchema#string

Satish K Tickoo

http://www.w3.org/2001/XMLSchema#string

P2860

The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters

The Iws1:Spt6:CTD complex controls cotranscriptional mRNA biosynthesis and HYPB/Setd2-mediated histone H3K36 methylation

The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1.

Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma

Frequent mutation of BAP1 in metastasizing uveal melanomas

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer

High-resolution profiling of histone methylations in the human genome

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Histone acetylation in chromatin structure and transcription

P304

848-854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2012.09.005

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

Omar Abdel-Wahab

Jonathan A. Coleman

P577

2012-09-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232086123

http://www.w3.org/2001/XMLSchema#string

P698

23036577

http://www.w3.org/2001/XMLSchema#string

P932

3615105

http://www.w3.org/2001/XMLSchema#string